









Markets
/
Stocks
/
nasdaq-onc
/

Beigene Ltd

ONC

353.920USD

+6.920+1.99%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

36.02BMarket Cap

575.45P/E TTM



Beigene Ltd

353.920

+6.920+1.99%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Beigene Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Beigene Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 392.09.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beigene Ltd's Score

Industry at a Glance

Industry Ranking

11 / 392

Overall Ranking

91 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Beigene Ltd Highlights

StrengthsRisks

BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 169.10% year-on-year.

Overvalued

The company’s latest PE is 575.45, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 34.32M shares, decreasing 11.77% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 340.00 shares of this stock.

Analyst Rating

Based on 24 analysts

Buy

Current Rating

392.087

Target Price

+12.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Beigene Ltd is 9.47, ranking 2 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.41B, representing a year-over-year increase of 41.00%, while its net profit experienced a year-over-year increase of 202.88%.

Score

Industry at a Glance

Previous score

9.47

Change



Financials

9.58

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Beigene Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Beigene Ltd is 7.49, ranking 114 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 575.45, which is 6.65% below the recent high of 613.74 and 136.32% above the recent low of -209.02.

Score

Industry at a Glance

Previous score

7.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Beigene Ltd is 8.42, ranking 123 out of 392 in the Biotechnology & Medical Research industry. The average price target is 396.00, with a high of 448.00 and a low of 250.00.

Score

Industry at a Glance

Previous score

8.42

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 24 analysts

Buy

Current Rating

392.087

Target Price

+12.99%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Beigene Ltd

ONC

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Beigene Ltd is 9.17, ranking 32 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 364.53 and the support level at 334.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.01

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

1.338

Buy

RSI(14)

60.701

Neutral

STOCH(KDJ)(9,3,3)

83.797

Buy

ATR(14)

10.492

Low Volatility

CCI(14)

84.238

Neutral

Williams %R

4.979

Overbought

TRIX(12,20)

0.306

Sell

StochRSI(14)

96.251

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

348.860

Buy

MA10

345.863

Buy

MA20

342.942

Buy

MA50

329.192

Buy

MA100

330.751

Buy

MA200

302.531

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Beigene Ltd is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 31.29%, representing a quarter-over-quarter decrease of 14.29%. The largest institutional shareholder is PRIMECAP Management, holding a total of 5.08M shares, representing 4.63% of shares outstanding, with 0.40% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Amgen Inc

18.94M

Baker Bros. Advisors LP

8.80M

PRIMECAP Management Company

Star Investors

5.08M

-0.15%

Capital International Investors

5.05M

+3.30%

Fidelity Management & Research Company LLC

3.76M

+10.12%

HHLR Advisors, Ltd.

1.03M

Temasek Holdings Pte. Ltd.

1.01M

+0.10%

T. Rowe Price International Ltd

941.86K

+1.07%

T. Rowe Price Associates, Inc.

Star Investors

688.71K

+680.59%

Invus Public Equities Advisors, LLC

492.99K

-3.33%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Beigene Ltd is 7.02, ranking 19 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.